Company / Cost of Revenue
BeOne Medicines Ltd. Cost of Revenue History
FY2016-FY2022 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$286.5M
FY2022
5-year range
$164.9M / $286.5M
FY2018-FY2022
Trend
+73.7%
vs FY2021
Sector context
#31 of 85
Health Care
What the data says
At $286M, BeOne Medicines Ltd.'s cost of revenue ranks #55 of 85 in the Health Care sector. Increased from $71M to $286M over the past 2 years.
Based on SEC 10-K filings.
$286M in FY2022 with a 5-year CAGR of +124.9%.
Increased from $71M to $286M over the past 2 years.
Health Care sector context is included.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- +59.1%
- 5-Year CAGR
- +124.9%
- 10-Year CAGR
- -
Sector benchmark
#55 of 85 in Health CareTop 64% of 85This company $286.5M Sector average $2.0B
▼
-85.6% below sector average
Key checks
Key Insights
- 5-year CAGR of +124.9%, indicating consistent growth.
- In FY2022, cost of revenue increased 73.7% year-over-year.
- Ranks #31 out of 85 companies in the Health Care sector.
- Lowest cost of revenue in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 0.82 (distress zone, below 1.8 threshold)
- Negative profit margin: -16.9%
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | $286.5M | +73.7% |
| FY2021 | $164.9M | +133.4% |
| FY2020 | $70.7M | -0.7% |
| FY2019 | $71.2M | +148.0% |
| FY2018 | $28.7M | +477.1% |
| FY2017 | $5.0M | - |
| FY2016 | $0 | - |
As of FY2022 · SEC 10-K · Updated Feb 28, 2026